ADMA Q3 2017 Earnings — ADMA Biologics, Inc. Revenue & Financial Results | Market Cap Arena

ADMAADMA Biologics, Inc.

$4B

Q3 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$5M+61.0% YoY

Gross Profit

-$7M-138.7% margin

Operating Income

-$14M-305.1% margin

Net Income

-$15M-321.5% margin

EPS (Diluted)

$-0.59

QoQ Revenue Growth

+39.1%

Cash Flow

Operating Cash Flow

-$10M

Free Cash Flow

-$10M

Stock-Based Comp.

$505,730

Balance Sheet

Total Assets

$73M

Total Liabilities

$60M

Stockholders' Equity

$13M

Cash & Equivalents

$14M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5M	$3M	+61.0%
Gross Profit	-$7M	$1M	-645.9%
Operating Income	-$14M	-$4M	-286.1%
Net Income	-$15M	-$4M	-251.0%